Brief: Knight Therapeutics Announces Regulatory Submission Of Pemigatinib In Brazil
10/10/2023 22:25
Oct 10 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ANNOUNCES REGULATORY SUBMISSION OF
PEMIGATINIB IN BRAZIL
* KNIGHT THERAPEUTICS-SUBMITTED MARKETING AUTHORIZATION
APPLICATION FOR PEMIGATINIB TO ANVISA, THE BRAZILIAN HEALTH
REGULATORY AGENCY
Source text for Eikon: ID:nGNXcgdTxw
Further company coverage: GUD.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil